Intellia Therapeutics Inc (NASDAQ:NTLA) traded up 5.1% during trading on Wednesday . The stock traded as high as $26.44 and last traded at $25.80. 835,134 shares traded hands during mid-day trading, a decline of 13% from the average session volume of 955,924 shares. The stock had previously closed at $24.54.

NTLA has been the subject of several recent analyst reports. Jefferies Group set a $42.00 target price on shares of Intellia Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. Oppenheimer reaffirmed a “hold” rating on shares of Intellia Therapeutics in a report on Monday, December 18th. BidaskClub raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. ValuEngine downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, Leerink Swann upped their target price on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Intellia Therapeutics currently has a consensus rating of “Hold” and an average price target of $30.17.

The firm has a market cap of $883.38, a price-to-earnings ratio of -16.54 and a beta of 3.60.

In related news, CEO Nessan Bermingham sold 336,783 shares of the stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $20.78, for a total value of $6,998,350.74. Following the completion of the transaction, the chief executive officer now owns 696,000 shares of the company’s stock, valued at approximately $14,462,880. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $18.30, for a total transaction of $27,870,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,521,928 shares of company stock valued at $51,883,434 in the last three months. Insiders own 12.80% of the company’s stock.

Several large investors have recently made changes to their positions in NTLA. Schwab Charles Investment Management Inc. lifted its holdings in shares of Intellia Therapeutics by 58.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 42,674 shares of the company’s stock valued at $683,000 after acquiring an additional 15,771 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Intellia Therapeutics by 73.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 54,802 shares of the company’s stock valued at $876,000 after acquiring an additional 23,126 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Intellia Therapeutics by 176.1% in the 2nd quarter. Wells Fargo & Company MN now owns 30,215 shares of the company’s stock valued at $483,000 after acquiring an additional 19,270 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Intellia Therapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 30,400 shares of the company’s stock valued at $486,000 after acquiring an additional 4,600 shares during the last quarter. Finally, Teachers Advisors LLC lifted its holdings in shares of Intellia Therapeutics by 135.3% in the 2nd quarter. Teachers Advisors LLC now owns 26,070 shares of the company’s stock valued at $417,000 after acquiring an additional 14,991 shares during the last quarter. 48.11% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Intellia Therapeutics (NTLA) Trading 5.1% Higher” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/intellia-therapeutics-ntla-trading-5-1-higher.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.